What Is Tzield?

Tzield (teplizumab-mzwv) is a medicine that can help delay type 1 diabetes. Tzield is known as a disease-modifying therapy because it helps slow the disease process rather than just manage blood sugar levels. It is used in people with stage 2 type 1 diabetes who are at risk of developing stage 3 disease. Unlike standard diabetes treatments, Tzield works before symptoms begin. It targets the immune system and helps slow the attack on insulin-producing beta cells in the pancreas. This may help the body produce insulin for longer.

What Is Teplizumab-mzwv?

Teplizumab-mzwv is the active ingredient in Tzield. It is a type of medicine called a monoclonal antibody. The treatment works by changing how the immune system behaves. This helps slow the attack on insulin-producing beta cells in the pancreas. Tzield is given through an intravenous (IV) infusion.

Who Manufactures Tzield?

Tzield is made by Sanofi, a global healthcare company that develops medicines for serious and chronic diseases.

Why Is Tzield Considered a Disease-Modifying Therapy?

Most diabetes treatments help control blood sugar after symptoms appear. Tzield works differently. It targets the immune system process that causes type 1 diabetes. By helping protect beta cells, it can delay the move from stage II to stage III type 1 diabetes. This is why it is called a disease-modifying therapy.

How Does Tzield Work?

Type 1 diabetes develops when the immune system attacks healthy beta cells in the pancreas. These cells make insulin, a hormone that helps control blood sugar. Over time, the attack damages the cells and reduces insulin production.

Understanding the Autoimmune Process in Type 1 Diabetes

The immune system uses white blood cells called T cells to fight infections. In people with type 1 diabetes, some T cells mistakenly attack the body's own beta cells. This ongoing attack can eventually lead to diabetes.

How Tzield Targets CD3-Positive T Cells

Tzield attaches to a protein called CD3 on certain T cells. This helps calm the immune response and slows the attack on beta cells. As a result, fewer beta cells are damaged.

Protecting Insulin-Producing Beta Cells

Tzield protects the surviving beta cells by delaying the immune response. This allows the pancreas to continue to make insulin for longer and may delay the onset of symptoms.

Who Is Eligible for Tzield?

Tzield is approved for people with stage II type 1 diabetes who are at risk of developing stage III disease.

Stage 2 Type 1 Diabetes Eligibility Criteria

A person may qualify for Tzield if they

• Have two or more type 1 diabetes autoantibodies

• Show signs of abnormal blood sugar levels (dysglycemia)

• Do not yet have symptoms of type 1 diabetes

Approved Age Groups

Tzield is approved for adults and children aged eight years and older who meet the eligibility requirements.

How Doctors Diagnose Stage 2 Type 1 Diabetes

Doctors may use several tests to diagnose stage II type 1 diabetes, including:

• Autoantibody tests.

• Oral glucose tolerance tests (OGTT).

• Fasting blood glucose tests.

• HbA1c tests.

These tests help identify people who have a high risk of developing type 1 diabetes.

What Are the Stages of Type 1 Diabetes?

Type 1 diabetes develops in stages. Understanding these stages can help identify people who may benefit from early treatment.

Stage 1: Autoantibodies, No Symptoms

Stage I: The person has two or more autoantibodies associated with diabetes. Still normal blood sugars. No symptoms. But the chance of having type 1 diabetes is significant.

Stage 2: Dysglycemia Before Symptoms Appear

In stage II, blood sugar levels start to become abnormal. The person still does not have symptoms, but beta-cell damage is continuing.

Stage 3: Symptomatic Type 1 Diabetes

Stage III is when symptoms begin to appear. Common symptoms include:

• Increased thirst.

• Frequent urination.

• Unexplained weight loss.

• Tiredness.

• Blurred vision.

At this stage, insulin treatment is usually needed.

How Effective Is Tzield?

Studies show that Tzield can delay the development of stage III type 1 diabetes in eligible patients.

Clinical Trial Results and Delayed Progression

Clinical trials found that people who received Tzield developed type 1 diabetes later than those who received a placebo. This means the treatment can slow disease progression.

Average Time Gained Before Stage III Diabetes

Research shows that Tzield delayed the onset of stage III type 1 diabetes by about two years on average. Some people experienced even longer delays.

Long-Term Benefits of Preserving Beta-Cell Function

Keeping beta cells healthy for longer may offer several benefits, including:

• Longer natural insulin production

• Better blood sugar control

• Lower risk of some diabetes-related complications

• More time before insulin therapy becomes necessary

How Is Tzield Administered?

You cannot take the Tzieild injection alone. Doctors or trained healthcare professionals give Tziels an intravenous injection (IV) in the medical centers. Also, trained health care personnel can come and give it to you at home.

The 14-day Infusion Schedule

Tzield injections follow a 14-day schedule. The dose depends on your body surface area. Your daily dose will increase for the first 4 days and will remain the same for the next 11 days. The dose schedule is as follows: 65, 125, 250, 500 micrograms (μ)/square meter for the first four days and 1030 micrograms (μ)/square meter for the remaining 11 days.

What to Expect During Treatment

As it is given through an intravenous drip, it takes almost 30 minutes to give. As it can cause issues, blood tests like blood count and liver function tests are done before it. To this. Also, doctors can ask you to take medicines like non-steroidal anti-inflammatory drugs (NSAIDs) and antiemetics to lower your side effects. Apart from this, doctors will monitor you throughout the time of administration.

Infection Risks and Laboratory Monitoring

Tzield works on the immune system. As it suppresses the immune system, it can lead to bacterial and viral infections. Infections like,

1. Epstein-Barr virus (EBV).

2. Cytomegalovirus (CMV).

Are very common during the treatment. Also, bacterial infection can lead to complications like

1. Gastroenteritis.

2. Pneumonia.

3. Cellulitis.

4. Abscesses and sepsis.

This happens due to a temporary drop in the white blood cell count (lymphocytes). This is constant monitoring is important.

How Can Patients Get Tested for Stage II Type 1 Diabetes?

Tests are done for diabetes-related autoantibodies in such cases; also, if you have a mild rise in the blood sugar level, you need to be tested.

Autoantibody Screening

Antibodies that are related to stage II type 1 diabetes include,

• ICA: Islet cell cytoplasmic autoantibodies.

• GAA/GAD: Glutamic acid decarboxylase autoantibodies.

• IA-2: Insulinoma-associated-2 autoantibodies.

• (IAA): Insulin autoantibodies.

• ZnT8A: Zinc transporter 8 autoantibodies.

Blood Glucose Testing

Blood tests are useful to detect changes in the blood sugar level. The following tests are effective.

1. Continuous Glucose Monitoring (CGM): This helps to monitor your glucose level continuously, and minor changes can be detected.

2. Self-Monitoring of Blood Glucose (SMBG): A traditional finger test is effective to a change in the blood sugar level.

When to Talk to a Healthcare Provider

If you have the following symptoms, you should talk to the doctor;

• Increased thirst.

• Excessive urge or excessive or frequent urination.

• Rapid unexplained loss of weight.

Is Tzield Available Worldwide?

No, Tzield is not available in all countries. However, it is getting approval in countries like the United States, the United Kingdom, the European Union (under the name Teizeild), China, and Australia.

FDA Approvals & Recent Label Expansions

Tzield was first approved by the FDA on 17 November 2022. On June 13, 2026, the Food and Drug Administration (FDA) granted fast-track approval status for pediatric patients with stage III type 1 diabetes.

Access and Insurance Considerations

Tzield treatment can come under insurance consideration. However, proper medical assessment and consideration are needed for type 1 diabetes stages for such cases.

Conclusion:

As Tzield belongs to the disease-modifying group of drugs, it can slow down the progression of type 1 diabetes. The active ingredient of this drug, Teplizumab-mzwv, is a type of monoclonal antibody that acts on your immune system. It slows down the damage to the beta cells of your pancreas, which produce insulin. Unlike insulin, you can not take it yourself; only healthcare providers can administer this medicine to you. If you have any queries regarding it, talk to the diabetologist online.

Key Takeaways

• Tzield is a disease-modifying drug that acts on our immune system and prevents damage to the beta cells.

• It is effective in the treatment of stage III type 1 diabetes.

• It is an FDA-approved medicine that has received its recent approval for pediatric use.